RxDoctor Payments Data

Andrew Benton, MD

Family Medicine · Greenwood, INNPI 1336553858

Payments from drug & device makers

$7,562in general payments, 2019–2025

Across 559 payments — averaging $13.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • GSK$449
  • Lilly USA, LLC$421
  • Pfizer$347
  • Merck$336
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$7,562100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,562 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$96,443
Medicare patients
236
Services billed
1,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$126,533
EliquisApixaban92$94,704
FarxigaDapagliflozin Propanediol76$76,841
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$61,549
VraylarCariprazine Hcl28$51,475
MounjaroTirzepatide41$44,930
RybelsusSemaglutide18$29,183
Breo ElliptaFluticasone/Vilanterol52$27,679
MyrbetriqMirabegron28$24,911
XareltoRivaroxaban20$19,818
JardianceEmpagliflozin16$18,566
RexultiBrexpiprazole12$18,254
TrulicityDulaglutide13$17,871
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$17,624
GemtesaVibegron12$15,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,140$155,71692 claims
PfizerEliquis$347$94,70492 claims
AstraZenecaFarxiga, Breztri Aerosphere$228$94,466101 claims
GSKTrelegy Ellipta, Breo Ellipta$449$89,228125 claims
Lilly USA, LLCMounjaro, Trulicity$421$62,80154 claims
AbbVieVraylar, Linzess, Synthroid$2,071$62,51382 claims
Astellas Pharma US IncMyrbetriq$121$24,91128 claims
Johnson & JohnsonXarelto$53$19,81820 claims
Boehringer IngelheimJardiance$152$18,56616 claims
Otsuka America Pharmaceutical, Inc.Rexulti$219$18,25412 claims
Sumitomo Pharma America, Inc.Gemtesa$19$15,22512 claims
MerckJanuvia$336$10,51013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Greenwood

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →